Program
CCRM Australia Business of Regenerative Medicine Asia Pacific – Australia China Science and Innovation Joint Program 2023.
25th to 27th June 2023
Day 0: 25th June 2023 - Intercontinental Suzhou
Dinner Reception | 1730 | Registration | |
|---|---|---|---|
1800 | Dinner reception and welcoming address: Silvio Tiziani - CEO CCRM Australia | ||
1810 | Reception address: Prof Jian Li - Head, Laboratory of Antimicrobial Systems | ||
1830 | Networking | ||
Day 1: 26th June 2023 - Suzhou Industrial Park Monash Research Institute of Science and Technology
Welcome and keynote. | 0830 | Registration opens and networking (including refreshments) | |
|---|---|---|---|
0850 | Opening address: Mr Silvio Tiziani | ||
0900 | Day 1 Welcoming address – Peter Cai, CEO National Foundation for Australia-China Relations | ||
Opening address, acknowledgements, announcements – Prof Sue Elliot - Provost & Senior Vice-President, Office of the Provost & Senior Vice-President | |||
Opening address, acknowledgements, announcements –Liu Bing, Deputy Consul-General and Senior Trade and Investment Commissioner at the Australian Consulate-General in Shanghai | |||
| Opening address, acknowledgements, announcements –Liu Bing, Senior Trade and Investment Commissioner and Deputy Consul-General (Commercial) | |||
Opening address, acknowledgements, announcements - Nick Henderson Deputy Commissioner, Greater China. State Government of Victoria, Australia | |||
| Opening address, acknowledgements, announcements –Dr Benjin Luo, Chief Scientist. National Innovation Center par Excellence (NICE) /Jiangsu Industrial Technology Research Institute (JITRI) | |||
0930 | Keynote Presentation: Opportunities in health technology and biomedical research to collaborate and re-engage post the relaxation of global COVID-19 restrictions: Prof James Whisstock, Deputy Dean Research, Monash University Faculty of Medicine, Nursing and Health Sciences | ||
1030 | Coffee Break and networking | ||
Session 1: Commercialisation | 1100 | A practical guide to IP: Dr Malcom Lyons, Principal, Griffith Hack | |
1130 | The commercialisation path for tissue regeneration & cell/gene therapy: Mark Leong Chairman Osteopore Ltd and Joy Song Co-founder Cellheal Therapeutics | ||
1200 | Lunch and networking | ||
Session 2: Onocology and Immunology. Chair: A/Prof Michael Gantier | 1300 | Tuning the reactogenicity of RNA therapeutics: A/Prof Michael Gantier - ARC Future Fellow and Group Leader, Hudson Institute of Medical Research | |
1330 | Pro-survival protein A1 limits pathogen-induced myeloid cell death and inflammatory responses: A/Prof Kathryn Lawlor, ARC Future Fellow - Hudson Institute | ||
1400 | Engineering Immune Cells for Cancer Therapy: Dr Roland Shu, Deputy CSO Cartherics | ||
1430 | Coffee Break and Networking, Announcements | ||
Session 3: Solving unmet clinical needs through medical technologies: from innovation to commercialisation Chair: Prof Patrick Kwan | 1500 | Engaging clinicians in Medtech. Experience of the Monash Institute of Medical Engineering: Prof Patrick Kwan, Co-Director Monash Institute of Medical Engineering (MIME)Monash University & Director, Epilepsy Unit, Brain Program, Alfred Hospital | |
| 1530 | Crossing the “Valley of Death”: Experience of the Monash MedTech Commercialisation Advancement Program: Prof John Forsythe - Co-Director - Monash Institute of Medical Engineering (MIME) Monash University | ||
| 1600 | Turning Research into Products: Experience from a MedTech Start-up: Lynn Chen - General Manager - Changzhou Trendi Medical Technology, Jiangsu province, China | ||
| 1630 | End of Day 1: Prof Jian Li - Monash University | ||
Day 2: 27th June 2023 - Kempinski Hotel Suzhou
Welcome | 0900 | Day 2 opens and networking (including refreshments) | |
|---|---|---|---|
0930 | Keynote presentation: Translational research of extracellular vesicle biomarkers: Dr Fred Li. Co-founder & CEO Carrier (Suzhou) Biomedical Co.Ltd. | ||
1030 | Coffee Break and Networking, Announcements | ||
Session 4: Commercialisation | 1100 | Development of Next-Generation Therapies from Pluripotent Stem Cells: Dr Matthew McCormack, Senior Director, iCamuno Biotherapeutics | |
1130 | Managing complex cell and gene therapy manufacturing: Sarah Bresse Managing Director. Masters Control. | ||
1200 | Lunch and networking | ||
Session 5: Antimicrobials and infectives Chair: Prof Jian Li | 1300 | Advantages and Clinical development of a myeloid-derived antimicrobial peptide: Prof Hong Sui. MD. Medical Director, Zhejiang Echon Biopharm, China. | |
1330 | A potpourri of lipopeptides to combat the antibiotics crisis: A/Prof Tony Velkov. PhD. Biomedicine Discovery Institute, Monash University, Australia | ||
1400 | Chinese pharmaceutical industry in antibiotics: Challenges and opportunities: Mr Jia (Jason) Wei. Medical Marketing Manager, SPH No. 1 Biochemical & Pharmaceutical, Shanghai Pharmaceuticals, China. | ||
1430 | Coffee Break and Networking, | ||
Session 6: Chair: Silvio Tiziani | 1530 | Examples of translational research at Monash University to develop new transformational treatment approaches for people with epilepsy: Prof Patrick Kwan. Co-Director Monash Institute of Medical Engineering (MIME)Monash University & Director, Epilepsy Unit, Brain Program, Alfred Hospital | |
1600 | Clinical microbiological diagnosis: Seeing is not always believing: Prof Jian Li - Monash University | ||
1630 | Closing address: Silvio Tiziani | ||
1645 | Symposium closes | ||
1800 | Forum Dinner at Kempinsky Hotel. | ||